US FDA approves Mesoblast's cell therapy for graft-versus-host disease
(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast (NASDAQ:MESO)'s cell therapy for treating a type of complication that occurs after a stem cell or...